Takeda
-
Takeda, Biological E collaborate for dengue vaccine in endemic areas
Biological E to manufacture up to 50 million doses of QDENGA Per Year Takeda and Biological E announced a strategic…
Read More » -
Takeda partners with BIRAC
The local-to-global initiative will support healthcare innovation and technological advancement for comprehensive solutions catering to healthcare needs Takeda signed a…
Read More » -
Global healthcare leaders advance sector decarbonisation ahead of COP28
China and India are key markets for pharmaceutical manufacturing, estimated to account for up to 50 per cent of materials…
Read More » -
Takeda announces favourable Phase 3 Safety and Efficacy Results of TAK-755
Results are from the first and only Phase 3 Trial in cTTP, an ultra-rare disease with limited treatment options Takeda…
Read More » -
Pharma giants partner with Singapore researchers to boost innovation in biologics and vaccines manufacturing
The partnership will be formalised through the Biologics Pharma Innovation Programme Singapore Leading pharma companies GSK, Sanofi and Takeda will…
Read More » -
US FDA grants priority review of Takeda’s Biologics License Application (BLA) for dengue vaccine candidate
Regulatory reviews will also progress in dengue-endemic countries in Latin America and Asia The US Food and Drug Administration (FDA)…
Read More » -
Takeda, Frazier Healthcare partner to launch HilleVax
Takeda has granted a license to HilleVax for the exclusive development and commercialisation rights to its norovirus vaccine candidate Takeda…
Read More » -
Takeda India launches diagnostic programme for rare disease
The programme will support improved diagnostic pathways for patients with LSDs such as Gaucher disease, Fabry disease, and mucopolysaccharidosis Type…
Read More » -
Takeda launches mobile application on genetic diseases
The XPERT EASE App will support HCPs withdose calculation for the treatment of patients with lysosomal storage disorders Takeda India…
Read More »